Bio Blast Pharma Ltd. (ORPN) Stock Price, Forecast & Analysis

NASDAQ:ORPN

11.5
+0.72 (+6.68%)
Last: Mar 25, 2019, 09:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

ORPN Key Statistics, Chart & Performance

Key Statistics
Market Cap4.81M
Revenue(TTM)N/A
Net Income(TTM)-5.95M
Shares418.00K
Float287.87K
52 Week High30
52 Week Low6.16
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-14.32
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
ORPN short term performance overview.The bars show the price performance of ORPN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

ORPN long term performance overview.The bars show the price performance of ORPN in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of ORPN is 11.5 null. In the past month the price increased by 5.7%. In the past year, price decreased by -27.4%.

Bio Blast Pharma Ltd. / ORPN Daily stock chart

ORPN Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ORPN. When comparing the yearly performance of all stocks, ORPN is one of the better performing stocks in the market, outperforming 85.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
ORPN Full Technical Analysis Report

ORPN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ORPN. While ORPN seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ORPN Full Fundamental Analysis Report

ORPN Financial Highlights

Over the last trailing twelve months ORPN reported a non-GAAP Earnings per Share(EPS) of -14.32. The EPS increased by 64.55% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -164.14%
ROE -188.01%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-45.82%
Sales Q2Q%N/A
EPS 1Y (TTM)64.55%
Revenue 1Y (TTM)N/A
ORPN financials

ORPN Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-100%
Revenue Next YearN/A
ORPN Analyst EstimatesORPN Analyst Ratings

ORPN Ownership

Ownership
Inst Owners4.47%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
ORPN Ownership

About ORPN

Company Profile

Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel.

Company Info

Bio Blast Pharma Ltd.

PO Box 318

Tel-Aviv Is 6100201

CEO: Fredric D. Price

Phone: 972-3573-6632

Bio Blast Pharma Ltd. / ORPN FAQ

What does ORPN do?

Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel.


What is the current price of ORPN stock?

The current stock price of ORPN is 11.5 null. The price increased by 6.68% in the last trading session.


Does ORPN stock pay dividends?

ORPN does not pay a dividend.


What is the ChartMill technical and fundamental rating of ORPN stock?

ORPN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.